Skip to main content

Table 3 The neutralizing antibody levels and protection against JEV infection in immunized mice

From: Multiple linear epitopes (B-cell, CTL and Th) of JEV expressed in recombinant MVA as multiple epitope vaccine induces a protective immune response

Treatment

PRNT50a

Survival rate (%)

Prime

1stboost

2ndboost

rMVA-mep

105TCID50

<5

<8

20±1.33

60c

106 TCID50

<7

9±1.33

33±2.33*

85c

107 TCID50

<8

18±2.33*

56±1.01**

100c

Inactivated JEV vaccine

9±1.33*

29±1.02**

58±2.01**

100c

EDIII

8±2.00*

28±1.99**

56±1.99**

100c

rMEP

9±1.01*

27±2.01**

57±1.99**

100c

Wild MVAb

--

--

--

0

PBSb

--

--

--

8.33

  1. a Prime-boost-boost vaccinations (days 0, 14 and 28) with rMVA-mep were carried out. On day 14 (prime), day 28 (first boost) and day 42 (second boost) sera were taken and analyzed. 50% plaque reduction neutralizing titer (PRNT50) was shown as the geometrical reciprocal of the sera dilution resulting in a 50% reduction.
  2. b No JEV-neutralizing antibodies were detectable in 1:2 diluted sera of the mice in the PBS and wild MVA groups. n = 12, values represent the mean ± standard error. Standard group is rMVA/M (105 TCID50).
  3. * Significance [p< 0.05 to animals immunized with rMVA/M (105TCID50)].
  4. **Significance [p<0.01 to animals immunized with rMVA/M (105TCID50)].
  5. c Significance (p< 0.05 to 8.33%).
Back to article page

Virology Journal

ISSN: 1743-422X